Thujone Exhibits Low Affinity for Cannabinoid Receptors But Fails to Evoke Cannabimimetic Responses

@article{Meschler1999ThujoneEL,
  title={Thujone Exhibits Low Affinity for Cannabinoid Receptors But Fails to Evoke Cannabimimetic Responses},
  author={Justin P Meschler and Allyn C. Howlett},
  journal={Pharmacology Biochemistry and Behavior},
  year={1999},
  volume={62},
  pages={473-480}
}

The Effects of Thujone on the Function of Nicotinic Acetylcholine Receptors

Thujone inhibits human nAChRs with different potencies using the two electrode voltage clamp method and was found to be independent of membrane potential and did not compete with ACh.

Modulation of GABAergic synaptic currents and current responses by α-thujone and dihydroumbellulone.

Analysis of current responses to exogenous GABA revealed that 1a reduced their amplitude, affecting their onset, desensitization, and deactivation, suggesting an effect on receptor gating, supporting the effects of 1a on GABAergic inhibition as being due to specific interactions with GABA(A)Rs.

Alpha-thujone (the active component of absinthe): gamma-aminobutyric acid type A receptor modulation and metabolic detoxification.

Alpha-thujone in absinthe and herbal medicines is a rapid-acting and readily detoxified modulator of the GABA-gated chloride channel.

Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development

An overview of therapeutic potential of ligands and plants modulating cannabinoid receptors that may be of interest to pharmaceutical industry in search of new and safer drug discovery and development for future therapeutics is provided.

Absinthe and gamma-aminobutyric acid receptors.

  • R. Olsen
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2000
Evidence that thujone acts as a γ-aminobutyric acid type A (GABAA) receptor chloride channel blocker, much like the plant convulsant picrotoxin, and related synthetic analogs is provided.

Thujone, a widely debated volatile compound: What do we know about it?

Experimental results show that the phenotypic manifestation and quantity of thujones in the essential oils depend on the plant organ and its developmental phase, and it would be necessary to do further systematic studies from the plant biological, toxicological and pharmaco-kinetic points of view to optimise the safe use ofThujones.

Thujone, a widely debated volatile compound: What do we know about it?

Experimental results show that the phenotypic manifestation and quantity of thujones in the essential oils depend on the plant organ and its developmental phase, as well as the weather conditions and growth habitat, which might influence the ratios and the possibly unique responses of the individual species.
...

References

SHOWING 1-10 OF 27 REFERENCES

Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model.

It is postulated that the receptor that is associated with the regulation of adenylate cyclase in vitro may be the same receptor as that mediating analgesia in vivo, and a conceptualization of the cannabinoid analgetic receptor is presented.

In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

It is not clear whether this pharmacological activity represents an uncharacterized action of SR141716A, or an index of tonic activity of an endogenous cannabinergic system, but it will be useful in establishing the biochemical events responsible for the in vivo effects of exogenous cannabinoids, as well as inestablishing the existence of a putative endogenous cannabinoidergic system.

Determination and characterization of a cannabinoid receptor in rat brain.

The criteria for a high affinity, stereoselective, pharmacologically distinct cannabinoid receptor in brain tissue have been fulfilled.

Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes.

  • A. Howlett
  • Biology, Chemistry
    Molecular pharmacology
  • 1985
It is inferred that the cannabimimetic compounds must act via regulatory mechanisms similar to those operating for receptor-mediated inhibition of adenylate cyclase, as well as by muscarinic cholinergic compounds.

Pharmacology of cannabinoid receptors.

  • A. Howlett
  • Biology, Chemistry
    Annual review of pharmacology and toxicology
  • 1995
Two subtypes of cannabinoid receptors, CB1 and CB2, have been described to date, although future investigations may elucidate other receptors, and three classes of agonist ligands regulate cannabinoid receptors: cannabinoid, aminoalkyl-indole, and eicosanoid derivatives.

Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

The ability of mu-opioid agonists to activate G proteins has been demonstrated by studying the binding of the GTP analogue guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTP gamma S) to membranes